All News
ACR23 – Day 3 Report
These year’s annual ACR Convergence has been a success with the return of an insanely active Poster Hall! F2F learning amidst miles of research and many young talented aside wizened establish presenters is such a welcome return to ACR, the way it should be.
Read Article
Should We Change How We Prescribe Methotrexate?
For as long as I can remember, methotrexate has been the anchor drug treatment of rheumatoid arthritis. We also know it has limited oral bioavailability at doses greater than 15mg. There are subcutaneous forms that offer better bioavailability, but its subcutaneous nature can sometimes sway patients away from trying it in addition to its higher cost. Split dosing of methotrexate can be a solution to attain higher bioavailability; however, its effect on clinical efficacy is unknown.
Read Article
#ACR23 Daily Recap Panel - Day 1
Join our live stream panel discussion as we dive deep into the highlights and key takeaways from day one of ACR 2023.
https://t.co/hApuycYzD2 https://t.co/1CD3rLLV7D
Dr. John Cush RheumNow ( View Tweet)
After 3 years, 25% (95% CI: 13 to 38) remained flare-free in the tapering TNFi group compared to 85% (70 to 93) in the stable TNFi group, hazard ratio for flare of 9.4 (3.9 to 22.8), ARCTIC REWIND, Kjorholt K, LB Abst#L07 #ACR23 #ACRBest @RheumNow https://t.co/fqxfU3jE0q https://t.co/J0qBeKNsEW
Dr. Antoni Chan ( View Tweet)
Palliative Care & Rheum - #ACR23 @RheumNow
Consider Pall Care for Serious Illness: "high mortality risk & negatively impacts function or QoL OR strains caregivers" - thats a lot of rheum pt
@HopkinsBayview-led session, always pt-centric
@kekuchinad @MymaAlbaydaMD @jhrheumatology https://t.co/1j4lrkb5Ra
Eric Dein ( View Tweet)
A memorable snap with the esteemed ACR rheumatologist, Dr. John Cush.
#ACR23
@RheumNow @ruby_taparia @Amansharmapgi
@eular_org
@ InRheumatology
@DandaDebashish
@drdpshenoy
@ DurgaPrasannaM1
@Amansharmapgi
@ docrota
@12VRavindran
@abledoc https://t.co/jfIrMDq8ue
Sarath Chandra Mouli Veeravalli 🇮🇳 ( View Tweet)
In this Ph2b RCT of TAK-279 (TYK2i), pts w/ PsA given 15mg & 30mg achieved an ACR20 response at wk 12 vs. PBO(53.3% and 54.2% vs 29.2%, both p = 0.002)
⬆️common TEAEs: Npharyngitis, URTI, headache & rash
#ACR23 ABSL12 @RheumNow https://t.co/T6swJgw6vE
sheila ( View Tweet)
Burden of flare & organ damage of SLE pts from the Asia Pacific cohort:
Prevalence of organ damage at BL - 39%
Incidence of damage accrual: ~58 per 1000PY
Pts w/ >=2 flares accrued damage
Flares independently⬆️risk of damage accrual
#ACR23 ABST2261 @RheumNow @rheumarhyme https://t.co/nW34sI9FdP
sheila ( View Tweet)
Auricular vagal nerve stimulation did not meaningfully improve RA disease activity. Further research of the novel intervention is required in RA, Baker MC, #ACR23 @RheumNow https://t.co/agLtRKdDTf
Dr. Antoni Chan ( View Tweet)
Kevin. Winthrop knocks it down on WHO is immunocompromised among rheumatic disease pts at Innovation Theater @CCalabreseDO #ACR23 @alhkim @AdamJBrownMD @ELittlejohnDO https://t.co/4hFtQgvaIf
Leonard Calabrese LCalabreseDO ( View Tweet)
#ACR23 Abstr#2332 We need to compliment the Complement #SLE. Post-hoc analysis of SOC + PBO from Dapirolizumab Phase 2 RCT showed reduced response in patients who flared with low complement levels vs normal or persistent activity. To consider as a stratifier @RheumNow https://t.co/BcN6ExLD0s
Md Yuzaiful Md Yusof ( View Tweet)
Come join us in 25 for the oral abstract session on #irAEs #ACR23 @jhrheumatology https://t.co/M3N9VCLNDb
Laura Cappelli ( View Tweet)
TM66 at #ACR23
60 yo M w/ worsening PMR symptoms (polyarthralgias, difficulty raising arms) & b/l vision loss
PMH: PMR, central serous chorioretinopathy, HTN
VS: 100.2 F, HR 108
Labs:
- CRP 100 mg/dL, ESR 81 mm/h
- UA: proteinuria (100 mg/dL)
- ANA > 1:10,000, dsDNA > 300… https://t.co/T7Nov5vyoc https://t.co/3GuXVgh03Z
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
Treatment of lupus nephritis #ACR23
Dall’Era M, Furie R, Mosca M
@RheumNow https://t.co/Md2DsOrY5F
Dr. Antoni Chan ( View Tweet)
TM61 at #ACR23
23 yo M p/w ~3mo of sternal swelling
- US probable abscess, drained + multiple abx w/ no improvement
- XR R shoulder + L elbow nl but MRI abn
- MRI L elbow: possible osteomyelitis (OM)
- MRI R shoulder; clavicular osteolysis
- Bone Bx clavicle + L Ulna: Chronic… https://t.co/7s9PIwByTs https://t.co/wKaKfnncP5
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
#ACR23 Late-Breaking Abstr#L10 Phase 2 crossover RCT of Dazodalibep, in #Sjogren pts with low ESSDAI but high ESSPRI. ESSPRI and FACIT-FATIGUE improved in both Stage 1 and also after X-over after 159 days. One to look out for those with high symptoms burden @RheumNow #ACRBest https://t.co/yGGrPmUOHU
Md Yuzaiful Md Yusof ( View Tweet)
🆕 2023 ACR Guidelines for Management of Interstitial Lung Disease (#ILD) in Systemic Autoimmune Rheumatic Diseases 🫁
🔸 Screening & Monitoring Recs
🔸 Treatment Guidelines ILD/RP-ILD
#RheumTwitter #PulmTwitter #MedTwitter #MedX https://t.co/JreVO0kgEf
Mithu Maheswaranathan, MD ( View Tweet)
👨⚖️ The Great Debate: should we use advanced therapies / biologics at disease onset in PMR & GCA? #ACR23
By Dr. Robert Spiera & Dr. Phil Seo @philseo #Vasculitis #PMR #GCA https://t.co/rkcUeEBLeZ
Mithu Maheswaranathan, MD ( View Tweet)
Part 2: Clinical Year in Review #ACR23 https://t.co/Yb8Xh2UKFY
Mithu Maheswaranathan, MD ( View Tweet)
Clinical Year in Review at #ACR23
By @philseo (@jhrheumatology)
Review some of the most impactful scientific studies in #Rheumatology in the past year! 🍕 https://t.co/ystEjzrU8u
Mithu Maheswaranathan, MD ( View Tweet)